Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Han Kiat Ong -- 1741 2023-01-18 04:21:19 |
2 update references and layout Amina Yu + 8 word(s) 1749 2023-01-18 04:40:52 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Aldoghachi, A.F.;  Chong, Z.X.;  Yeap, S.K.;  Cheong, S.K.;  Ho, W.Y.;  Ong, A.H.K. Mesenchymal Stroma/Stem Cells and Cancer. Encyclopedia. Available online: https://encyclopedia.pub/entry/40317 (accessed on 28 March 2026).
Aldoghachi AF,  Chong ZX,  Yeap SK,  Cheong SK,  Ho WY,  Ong AHK. Mesenchymal Stroma/Stem Cells and Cancer. Encyclopedia. Available at: https://encyclopedia.pub/entry/40317. Accessed March 28, 2026.
Aldoghachi, Ahmed Faris, Zhi Xiong Chong, Swee Keong Yeap, Soon Keng Cheong, Wan Yong Ho, Alan Han Kiat Ong. "Mesenchymal Stroma/Stem Cells and Cancer" Encyclopedia, https://encyclopedia.pub/entry/40317 (accessed March 28, 2026).
Aldoghachi, A.F.,  Chong, Z.X.,  Yeap, S.K.,  Cheong, S.K.,  Ho, W.Y., & Ong, A.H.K. (2023, January 18). Mesenchymal Stroma/Stem Cells and Cancer. In Encyclopedia. https://encyclopedia.pub/entry/40317
Aldoghachi, Ahmed Faris, et al. "Mesenchymal Stroma/Stem Cells and Cancer." Encyclopedia. Web. 18 January, 2023.
Mesenchymal Stroma/Stem Cells and Cancer
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms24021012

Human Mesenchymal stroma/stem cells (MSC) are heterogenous populations of multipotent stem cells that can be obtained from different origins, and among the most commonly studied are the bone marrow, adipose tissue, umbilical cord, Wharton’s jelly, dental pulp, and peripheral blood mononuclear cells. The international society for cell and gene therapy (ISCT) defined MSC as being able to adhere to plastic, positively express MSC markers (CD73, CD105, and CD90), negatively express hematopoietic markers (CD14, CD45, CD34, CD19, and HLA-DR), and have the ability to differentiate into adipogenic, chondrogenic, and osteogenic lineages . ISCGT also suggested that the termed mesenchymal stromal cells be used instead of mesenchymal stem cells for any fibroblast-like plastic-adherent cells, regardless of the tissue from which they are isolated, while keeping the same acronym “MSCs”.

MSC iPSC iMSC CSC exosomes miRNA

1. Mesenchymal Stroma/Stem Cells (MSC) Homing and Paracrine Interaction with Cancer

While studies have shown the various roles of MSCs in cellular functions, including the ability to differentiate into various cell types for damaged tissue repair and regeneration, current evidence has also pointed to the paracrine signaling mechanism [1][2] related to the release of several trophic factors including cytokines, chemokines, and extracellular matrix protein as well as exosomal miRNA into the surrounding cell environment. These paracrine signals were reported to be associated with immunomodulatory properties, angiogenesis, anti-apoptosis, anti-oxidation, anti-inflammation, and cell proliferation [1]. However, in the context of cell cancer interaction, paracrine signaling also promotes the migration of MSC to the tumor site [3] and has been known to either exert suppression or promotion of tumors within the tumor microenvironment (TME) [4]. Among the signaling molecules involved with MSC migration to the tumor site are CXCL12/CXCR4 [5], CCL2 in Breast cancer, and SDF-1 in colorectal, prostate, and breast cancers [6]. The recruitment of MSC to the cancer site can also be achieved via the interaction of MSC with certain cytokines responsible for angiogenesis (IL-8, TGF-β, and VEGF) that are secreted by cancer cells [7]. In addition, MMP-1, a component of the extracellular matrix, helps in stimulating MSC homing to the cancer site via PAR-1 cleavage and activation [8].

2. The Double Life of MSC in Cancer Interaction Studies

The dual role of MSC in cancer-related studies, as either promoting or suppressing cancer activities in cancer cells, is a much-accepted fact, with various reports linking MSC as a tumor enhancer via mediating angiogenesis, attenuating immune reactions, initiating epithelial to mesenchymal transition (EMT), and promoting metastatic processes whereas the tumoricidal effect of MSC on cancer cells appears to be more apparent through the induction of apoptosis and signaling pathways alterations [9].

2.1. MSC as a Tumor Enhancer

Several studies have revealed that MSCs can support the tumor vasculature via direct differentiation of MSCs into myofibroblasts that are were then transformed into tumor-associated fibroblasts (TAFs) [10] or indirectly via the secretion of several growth factors [11]. MSCs are capable of secreting several angiogenic factors (FGF-2, PDGF, VEGF, TGF-β, IL-6, IL-8, and angiopoietin-1) that facilitate angiogenesis leading to tumor-promoting features [12]. Additionally, the immunosuppressive effect of MSC contributes to cancer cells’ escape from the immune system surveillance. Due to their direct action on immune cells, MSCs are capable of inhibiting apoptosis or inhibition of T cell proliferation which results in a decline of immunogenic activity [13]. Furthermore, MSC has also shown pro-metastatic effects that are mediated via paracrine factors, including TGF-β, CXCR4, and CCL5; chemokines secreted from MSC [7][13][14]. Martin et al. (2010) revealed that the co-culture of bone marrow-derived MSC with breast cancer resulted in the overexpression of EMT-specific genes and a decrease of mesenchymal to epithelial (MET) genes [15]. Similarly, in a co-culture-based interaction study between an adipose-derived MSC (ADSC) and MCF-7 breast cancer and in an in vivo nude mouse model, MCF-7 cells were shown to exert tumor tropism effects on ADSCs, reportedly regulated by chemokines, such as the macrophage inflammatory protein (MIP)-1δ and MIP-3α. This effect was mediated by epithelial–mesenchymal transition, which significantly induced tumor sphere formation in vitro and promoted tumorigenicity in vivo [16]. The interaction of MSC with cancer cells can also result in the differentiation of MSC into carcinoma-associated fibroblasts (CAFs) via TGF- β resulting in stabilizing the tumor tissue at the primary and metastatic site and thus promoting cancer stemness as well as chemoresistance via paracrine factor secretions [17]. MSC-conditioned medium has been shown to upregulate BCl-2, an anti-apoptotic protein, and suppress the expression of P53 and BAX (apoptosis proteins) that resulted in inhibiting apoptosis, which in turn promoted colorectal cancer progression through AMPK/mTOR-mediated NF-κB activation [18].

2.2. MSC as a Tumor Suppressor

Mesbah et al. (2021) showed that the cultivation of colorectal cancer cells with MSC inhibited proliferation and induced apoptosis of colorectal cancer cells with increased expressions on P53, Caspase3, and P21. The tumoricidal or pro-neoplastic effect of MSC on cancer can also be attributed to its hypo- or hyper-activation of certain signaling pathways associated with cancer proliferation, survival, and progression [19]. Among the pathways involved are the ERK1/2, Wnt, PI3K/AKT, JAK/STAT, MYC, Hippo, and NF-kB pathways [20]. MSC-conditioned medium when cultured with head and neck squamous cell carcinoma cell lines resulted in enhancing cellular proliferation via the activation of ERK1/2 signaling in vitro [21]. Additionally, MSC administration into U251 glioma cells suppressed tumor growth and induced apoptosis via downregulating PI3K/AKT pathway [22]. Interestingly, a co-culture experiment on adipose-derived MSC (AD-MSC) with MCF7-luminal and MDA-MB-231-basal breast cancer cells demonstrated the possible influence of exosomal miRNA in promoting these cancer cells towards a more dormant-epithelial phenotype associated with lower metastasis potential but higher chemoresistance. The decrease in metabolic and cellular activities of these dormant cells was attributed to a possible form of evasion by the cancer cells from the effects of these drugs, which generally targeted rapidly proliferating cells, as well as the increased expression of drug resistance-related proteins triggered by MSC-exosomes [23].

2.3. Exosomal miRNA in Crosstalk between MSC and Cancer Cells

Another exciting development at the forefront of MSC and cancer therapy is the interaction between exosomal miRNA and cancer cells. The dysregulation of exosomal miRNA was shown to promote tumor growth due to the activation of angiogenic signaling pathways such as VEGF [24], hedgehog signaling pathway [25], and STAT3 [26]. Other studies reported on the effects of exosomal miRNA that decreased tumor growth were associated with NF-κB p65 activation [27], downregulation of VEGF expression [28], inhibition of Galectin-3 [29], regulation of KDM4B/HOXC4/PD-L1 axis [30], down-regulation of mTOR and S6KB1 expression [31], and down-regulation of trefoil factor 3 (TFF3) [32]. Examples of cancer studies involving exosomal miRNA are summarized in Table 1, and a comprehensive list of miRNA shown to be associated with various cancer types was previously reviewed by Galland et al. [4] as well as Dalmizrak and Dalmizrak [33]. Despite the complexities of MSC interaction with cancers in the respective TME, numerous exosomal miRNA were found to be directly associated with major cancer pathways (Table 1) and were shown to be promising anti-cancer delivery agents with potential as non-cell-based cancer therapy (Table 2).
Table 1. Studies on Exosomal miRNA involved in either tumor promotion or suppression.
Exosomal miRNA MSC Cancer Type Signaling Pathway Function Ref.
mrR-21
miR-34a		 Bone marrow Breast cancer Activation of (ERK1/2) pathway Promote tumor growth [24]
miR-221 Bone marrow Osteosarcoma (MG63) and gastric cancer (SGC7901) cells Activation of hedgehog signaling pathway. Promote tumor growth [25]
miR-193a-3p
miR-210-3p
miR-5100		 Bone marrow grown under hypoxic condition Lung cancer cells and an in vivo mouse syngeneic tumor model STAT3-induced EMT Promote cancer cell invasion and EMT. [26]
miR-221 Bone marrow Gastric cancer BGC-823 and SGC-7901 cells ND Proliferation, migration, invasion, and adhesion to the matrix of GC BGC-823 and SGC-7901 cells were significantly enhanced [34]
miR-100-5p
miR-9-5p
let-7d-5p		 Bone marrow Glioblastoma Activation of MSCs into (CAFs)-like cells Promote tumor growth via a decrease in anti-tumoral miR-100-5p, miR-9-5p, and let-7d-5p [35]
miR-17-5p
miR-615-5p		 Human adipose MSCs Hepatocellular carcinoma cell line (Huh-7 cells) Generation of cancer-associated phenotype of some CAF-like characteristics Promote tumor growth via upregulation of miR-17-5p and 615-5p [36]
miR-16 Bone marrow Mouse breast cancer cell line (4T1) Down-regulation of expressed VEGF in tumor cells Suppress tumor growth via inhibition of angiogenesis [28]
miRNA-1231 Bone marrow Pancreatic cancer ND Suppress tumor growth [37]
miRNA-16-5p Adipose-derived mesenchymal stem cells Breast cancer ND Suppress tumor growth [38]
miRNA-128-3p Human umbilical cord mesenchymal stem cell- Pancreatic ductal cell carcinoma Inhibiting galectin-3 Suppress pancreatic ductal cell carcinoma [29]
miR-15a Adipose-derived mesenchymal stem cells Colorectal cancer Restriction of immune evasion of CRC via the KDM4B/HOXC4/PD-L1 axis Suppress tumor growth [30]
miR-199a-3p T-MScs HepG2 cells. Potentially targeting CD151, integrin α3 and 6 Inhibit tumor growth and HepG2 cell migration [39]
miR-375 Enriched in bone marrow mesenchymal stem cells (BMSC) Prostate cancer cell Down-regulating trefoil factor 3 (TFF3) Inhibit migration and invasion [32]

Abbreviation: ERK1/2: extracellular signal-regulated kinase1/2; STAT3: signal transducer and activator of transcription 3; EMT: epithelial to mesenchymal transition; CAFs: cancer-associated fibroblasts; VEGF: vascular endothelial growth factor; KDM4B/HOXC4/PD-L1: lysine demethylase 4B/homeobox C4/programmed death-ligand 1; TFF3: trefoil factor 3; ND: not defined.

Table 2. Exosomal miRNA with potential as anti-cancer delivery agents.
Exosomal miRNA MSC Cancer Type Delivery Method Function/Target Ref.
miR 222/223 ND Immunodeficient mouse model of dormant breast cancer MSC transfected with antagomiR 222/223 ND [40]
microRNA-584 Human MSC (Origin ND) U87 human glioma cells Exosomes derived from microRNA-584 transfected mesenchymal stem cells Suppression of the expression of CYP2J2; reduced the levels of phosphorylated AKT and MAPK [41]
miRNA-221 Human cord blood mesenchymal stromal Colorectal carcinoma Cell-derived exosomes were used in the delivery of anti-miRNA oligonucleotides Anti-tumor efficacy [42]
miR-381-3p Mimic Adipose-derived mesenchymal stem cells MDA-MB-231 cells miR-381 loaded ADMSC-exosomes Downregulation of expressed related genes and proteins; inhibited proliferation, migration, and invasion capacity [43]
miR-34a Dental pulp MSCs (DPSCs) Breast carcinoma cells. miR-34a loaded modified dental pulp MSCs (DPSCs) exosomes Repression of tumor proliferation [44]
miR-30c-5p Human umbilical cord mesenchymal stem cells Papillary thyroid carcinoma (PTC) miR-30c-5p containing extracellular vesicles Tumor-suppressive miRNA targeted PELI1 to inhibit PTC cell proliferation and migration via activating PI3K/AKT pathway [45]
Let-7f miRNA Bone marrow-derived human mesenchymal stem cells 4T1 breast tumor model Let-7f miRNA containing extracellular vesicles Regulates SDF-1α- and hypoxia-promoted migration of mesenchymal stem cells [46]
MiR-199a- Adipose tissue-derived mesenchymal stem Hepatocellular carcinoma miR-199a-modified exosomes Improve chemosensitivity through mTOR [47]
miR-124 BM-MSC   miR-124 derived exosomes Anti-tumor effects on cell proliferation, epithelial–mesenchymal transition, and chemotherapy sensitivity [48]

Abbreviation: CYP2J2: cytochrome P450 2J2; AKT: serine/threonine kinase (protein kinase B); MAPK: mitogen-activated protein kinase; PELI1: pellino homolog 1; PI3K: phosphatidylinositol-3-kinase; SDF-1α: human stromal-derived factor 1; ND: not defined.

References

  1. Barzegar, M.; Kaur, G.; Gavins, F.; Wang, Y.; Boyer, C.; Alexander, J. Potential therapeutic roles of stem cells in ischemia-reperfusion injury. Stem Cell Res. 2019, 37, 101421.
  2. Park, S.-R.; Kim, J.-W.; Jun, H.-S.; Roh, J.Y.; Lee, H.-Y.; Hong, I.-S. Stem Cell Secretome and Its Effect on Cellular Mechanisms Relevant to Wound Healing. Mol. Ther. 2018, 26, 606–617.
  3. Ghaffari-Nazari, H. The known molecules involved in MSC homing and migration. J. Stem Cell Res. Med. 2018, 3, 1–4.
  4. Galland, S.; Stamenkovic, I. Mesenchymal stromal cells in cancer: A review of their immunomodulatory functions and dual effects on tumor progression. J. Pathol. 2019, 250, 555–572.
  5. Kalimuthu, S.; Oh, J.M.; Gangadaran, P.; Zhu, L.; Lee, H.W.; Rajendran, R.L.; Baek, S.H.; Jeon, Y.H.; Jeong, S.Y.; Lee, S.-W.; et al. In Vivo Tracking of Chemokine Receptor CXCR4-Engineered Mesenchymal Stem Cell Migration by Optical Molecular Imaging. Stem Cells Int. 2017, 2017, 8085637.
  6. Menon, L.G.; Picinich, S.; Koneru, R.; Gao, H.; Lin, S.Y.; Koneru, M.; Mayer-Kuckuk, P.; Glod, J.; Banerjee, D. Differential Gene Expression Associated with Migration of Mesenchymal Stem Cells to Conditioned Medium from Tumor Cells or Bone Marrow Cells. Stem Cells 2006, 25, 520–528.
  7. Christodoulou, I.; Goulielmaki, M.; Devetzi, M.; Panagiotidis, M.; Koliakos, G.; Zoumpourlis, V. Mesenchymal stem cells in preclinical cancer cytotherapy: A systematic review. Stem Cell Res. Ther. 2018, 9, 336.
  8. Chen, M.-S.; Lin, C.-Y.; Chiu, Y.-H.; Chen, C.-P.; Tsai, P.-J.; Wang, H.-S. IL-1β-Induced Matrix Metalloprotease-1 Promotes Mesenchymal Stem Cell Migration via PAR1 and G-Protein-Coupled Signaling Pathway. Stem Cells Int. 2018, 2018, 3524759.
  9. Zhuang, W.-Z.; Lin, Y.-H.; Su, L.-J.; Wu, M.-S.; Jeng, H.-Y.; Chang, H.-C.; Huang, Y.-H.; Ling, T.-Y. Mesenchymal stem/stromal cell-based therapy: Mechanism, systemic safety and biodistribution for precision clinical applications. J. Biomed. Sci. 2021, 28, 28.
  10. Barcellos-De-Souza, P.; Comito, G.; Pons-Segura, C.; Taddei, M.L.; Gori, V.; Becherucci, V.; Bambi, F.; Margheri, F.; Laurenzana, A.; Del Rosso, M.; et al. Mesenchymal Stem Cells are Recruited and Activated into Carcinoma-Associated Fibroblasts by Prostate Cancer Microenvironment-Derived TGF-β1. Stem Cells 2016, 34, 2536–2547.
  11. Hass, R.; Von Der Ohe, J.; Ungefroren, H. Impact of the Tumor Microenvironment on Tumor Heterogeneity and Consequences for Cancer Cell Plasticity and Stemness. Cancers 2020, 12, 3716.
  12. Liang, W.; Chen, X.; Zhang, S.; Fang, J.; Chen, M.; Xu, Y.; Chen, X. Mesenchymal stem cells as a double-edged sword in tumor growth: Focusing on MSC-derived cytokines. Cell. Mol. Biol. Lett. 2021, 26, 3.
  13. Hassanzadeh, A.; Altajer, A.H.; Rahman, H.S.; Saleh, M.M.; Bokov, D.O.; Abdelbasset, W.K.; Marofi, F.; Zamani, M.; Yaghoubi, Y.; Yazdanifar, M.; et al. Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy. Front. Cell Dev. Biol. 2021, 9, 686453.
  14. Oh, I.-R.; Raymundo, B.; Kim, M.; Kim, C.-W. Mesenchymal stem cells co-cultured with colorectal cancer cells showed increased invasive and proliferative abilities due to its altered p53/TGF-β1 levels. Biosci. Biotechnol. Biochem. 2019, 84, 256–267.
  15. Martin, F.T.; Dwyer, R.M.; Kelly, J.; Khan, S.; Murphy, J.M.; Curran, C.; Miller, N.; Hennessy, E.; Dockery, P.; Barry, F.P.; et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: Stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res. Treat. 2010, 124, 317–326.
  16. Chen, Y.; He, Y.; Wang, X.; Lu, F.; Gao, J. Adipose-derived mesenchymal stem cells exhibit tumor tropism and promote tumorsphere formation of breast cancer cells. Oncol. Rep. 2019, 41, 2126–2136.
  17. Aoto, K.; Ito, K.; Aoki, S. Complex formation between platelet-derived growth factor receptor β and transforming growth factor β receptor regulates the differentiation of mesenchymal stem cells into cancer-associated fibroblasts. Oncotarget 2018, 9, 34090–34102.
  18. Wu, X.-B.; Liu, Y.; Wang, G.-H.; Xu, X.; Cai, Y.; Wang, H.-Y.; Li, Y.-Q.; Meng, H.-F.; Dai, F.; Jin, J.-D. Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-κB activation. Sci. Rep. 2016, 6, 21420.
  19. Mesbah, N.; Barikrow, N.; Heshmati, M. Studying the suppressing effect of mesenchymal stem cells derived from amniotic membrane on colorectal cancer. J. Curr. Biomed. Rep. 2021, 2, 192–200.
  20. Lan, T.; Luo, M.; Wei, X. Mesenchymal stem/stromal cells in cancer therapy. J. Hematol. Oncol. 2021, 14, 195.
  21. Scherzad, A.; Steber, M.; Gehrke, T.; Rak, K.; Froelich, K.; Schendzielorz, P.; Hagen, R.; Kleinsasser, N.; Hackenberg, S. Human mesenchymal stem cells enhance cancer cell proliferation via IL-6 secretion and activation of ERK1/2. Int. J. Oncol. 2015, 47, 391–397.
  22. Lu, L.; Chen, G.; Yang, J.; Ma, Z.; Yang, Y.; Hu, Y.; Lu, Y.; Cao, Z.; Wang, Y.; Wang, X. Bone marrow mesenchymal stem cells suppress growth and promote the apoptosis of glioma U251 cells through downregulation of the PI3K/AKT signaling pathway. Biomed. Pharmacother. 2019, 112, 108625.
  23. Ali, N.M.; Yeap, S.K.; Ho, W.Y.; Boo, L.; Ky, H.; Satharasinghe, D.A.; Tan, S.W.; Cheong, S.K.; Da Huang, H.; Lan, K.C.; et al. Adipose MSCs Suppress MCF7 and MDA-MB-231 Breast Cancer Metastasis and EMT Pathways Leading to Dormancy via Exosomal-miRNAs Following Co-Culture Interaction. Pharmaceuticals 2020, 14, 8.
  24. Zhu, W.; Huang, L.; Li, Y.; Zhang, X.; Gu, J.; Yan, Y.; Xu, X.; Wang, M.; Qian, H.; Xu, W. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 2012, 315, 28–37.
  25. Qi, J.; Zhou, Y.; Jiao, Z.; Wang, X.; Zhao, Y.; Li, Y.; Chen, H.; Yangbin, L.; Zhu, H.; Li, Y. Exosomes Derived from Human Bone Marrow Mesenchymal Stem Cells Promote Tumor Growth Through Hedgehog Signaling Pathway. Cell. Physiol. Biochem. 2017, 42, 2242–2254.
  26. Zhang, X.; Sai, B.; Wang, F.; Wang, L.; Wang, Y.; Zheng, L.; Li, G.; Tang, J.; Xiang, J. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. Mol. Cancer 2019, 18, 1–15.
  27. Zhu, M.; Wang, M.; Yang, F.; Tian, Y.; Cai, J.; Yang, H.; Fu, H.; Mao, F.; Zhu, W.; Qian, H.; et al. miR-155-5p inhibition promotes the transition of bone marrow mesenchymal stem cells to gastric cancer tissue derived MSC-like cells via NF-κB p65 activation. Oncotarget 2016, 7, 16567–16580.
  28. Lee, J.-K.; Park, S.-R.; Jung, B.-K.; Jeon, Y.-K.; Lee, Y.-S.; Kim, M.-K.; Kim, Y.-G.; Jang, J.-Y.; Kim, C.-W. Exosomes Derived from Mesenchymal Stem Cells Suppress Angiogenesis by Down-Regulating VEGF Expression in Breast Cancer Cells. PLoS ONE 2013, 8, e84256.
  29. Xie, X.; Ji, J.; Chen, X.; Xu, W.; Chen, H.; Zhu, S.; Wu, J.; Wu, Y.; Sun, Y.; Sai, W.; et al. Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3. Clin. Transl. Oncol. 2021, 24, 517–531.
  30. Liu, L.; Yu, T.; Jin, Y.; Mai, W.; Zhou, J.; Zhao, C. MicroRNA-15a Carried by Mesenchymal Stem Cell-Derived Extracellular Vesicles Inhibits the Immune Evasion of Colorectal Cancer Cells by Regulating the KDM4B/HOXC4/PD-L1 Axis. Front. Cell Dev. Biol. 2021, 9, 629893.
  31. Khazaei-Poul, Y.; Shojaei, S.; Koochaki, A.; Ghanbarian, H.; Mohammadi-Yeganeh, S. Evaluating the influence of Human Umbilical Cord Mesenchymal Stem Cells-derived exosomes loaded with miR-3182 on metastatic performance of Triple Negative Breast Cancer cells. Life Sci. 2021, 286, 120015.
  32. Liang, Q.; Zhong, W. MiR-375 Enriched in Bone Marrow Mesenchymal Stem Cells (BMSC) Exosomes Inhibits Prostate Cancer Cell Migration and Invasion by Down-Regulating Trefoil Factor 3 (TFF3). J. Biomater. Tissue Eng. 2021, 11, 2407–2414.
  33. Dalmizrak, A.; Dalmizrak, O. Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer. Front. Bioeng. Biotechnol. 2022, 10, 1747.
  34. Ma, M.; Chen, S.; Liu, Z.; Xie, H.; Deng, H.; Shang, S.; Wang, X.; Xia, M.; Zuo, C. miRNA-221 of exosomes originating from bone marrow mesenchymal stem cells promotes oncogenic activity in gastric cancer. OncoTargets Ther. 2017, 10, 4161–4171.
  35. Garnier, D.; Ratcliffe, E.; Briand, J.; Cartron, P.-F.; Oliver, L.; Vallette, F.M. The Activation of Mesenchymal Stem Cells by Glioblastoma Microvesicles Alters Their Exosomal Secretion of miR-100-5p, miR-9-5p and let-7d-5p. Biomedicines 2022, 10, 112.
  36. Salah, R.A.; Nasr, M.A.; El-Derby, A.M.; Elkodous, M.A.; Mohamed, R.H.; El-Ekiaby, N.; Osama, A.; Elshenawy, S.E.; Hamad, M.H.M.; Magdeldin, S.; et al. Hepatocellular carcinoma cell line-microenvironment induced cancer-associated phenotype, genotype and functionality in mesenchymal stem cells. Life Sci. 2021, 288, 120168.
  37. Shang, S.; Wang, J.; Chen, S.; Tian, R.; Zeng, H.; Wang, L.; Xia, M.; Zhu, H.; Zuo, C. Exosomal miRNA-1231 derived from bone marrow mesenchymal stem cells inhibits the activity of pancreatic cancer. Cancer Med. 2019, 8, 7728–7740.
  38. Li, T.; Zhou, X.; Wang, J.; Liu, Z.; Han, S.; Wan, L.; Sun, X.; Chen, H. Adipose-derived mesenchymal stem cells and extracellular vesicles confer antitumor activity in preclinical treatment of breast cancer. Pharmacol. Res. 2020, 157, 104843.
  39. Choi, D.-W.; Cho, K.-A.; Kim, J.; Lee, H.-J.; Kim, Y.-H.; Park, J.-W.; Woo, S.-Y. Extracellular vesicles from tonsil-derived mesenchymal stromal cells show anti-tumor effect via miR-199a-3p. Int. J. Mol. Med. 2021, 48, 1–10.
  40. Bliss, S.A.; Sinha, G.; Sandiford, O.A.; Williams, L.M.; Engelberth, D.J.; Guiro, K.; Isenalumhe, L.L.; Greco, S.J.; Ayer, S.; Bryan, M.; et al. Mesenchymal stem cell–derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 2016, 76, 5832–5844.
  41. Kim, R.; Lee, S.; Lee, J.; Kim, M.; Kim, W.J.; Lee, H.W.; Lee, M.Y.; Kim, J.; Chang, W. Exosomes derived from microrna-584 transfected mesenchymal stem cells: Novel alternative therapeutic vehicles for cancer therapy. BMB Rep. 2018, 51, 406–411.
  42. Han, S.; Li, G.; Jia, M.; Zhao, Y.; He, C.; Huang, M.; Jiang, L.; Wu, M.; Yang, J.; Ji, X.; et al. Delivery of Anti-miRNA-221 for Colorectal Carcinoma Therapy Using Modified Cord Blood Mesenchymal Stem Cells-Derived Exosomes. Front. Mol. Biosci. 2021, 8.
  43. Shojaei, S.; Hashemi, S.M.; Ghanbarian, H.; Sharifi, K.; Salehi, M.; Mohammadi-Yeganeh, S. Delivery of miR-381-3p Mimic by Mesenchymal Stem Cell-Derived Exosomes Inhibits Triple Negative Breast Cancer Aggressiveness; an In Vitro Study. Stem Cell Rev. Rep. 2021, 17, 1027–1038.
  44. Vakhshiteh, F.; Rahmani, S.; Ostad, S.N.; Madjd, Z.; Dinarvand, R.; Atyabi, F. Exosomes derived from miR-34a-overexpressing mesenchymal stem cells inhibit in vitro tumor growth: A new approach for drug delivery. Life Sci. 2020, 266, 118871.
  45. Zheng, T.; Zhou, Y.; Xu, X.; Qi, X.; Liu, J.; Pu, Y.; Zhang, S.; Gao, X.; Luo, X.; Li, M.; et al. MiR-30c-5p loss-induced PELI1 accumulation regulates cell proliferation and migration via activating PI3K/AKT pathway in papillary thyroid carcinoma. J. Transl. Med. 2022, 20, 20.
  46. Egea, V.; Kessenbrock, K.; Lawson, D.; Bartelt, A.; Weber, C.; Ries, C. Let-7f miRNA regulates SDF-1α- and hypoxia-promoted migration of mesenchymal stem cells and attenuates mammary tumor growth upon exosomal release. Cell Death Dis. 2021, 12, 516.
  47. Lou, G.; Chen, L.; Xia, C.; Wang, W.; Qi, J.; Li, A.; Zhao, L.; Chen, Z.; Zheng, M.; Liu, Y. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway. J. Exp. Clin. Cancer Res. 2020, 39, 4.
  48. Xu, Y.; Liu, N.; Wei, Y.; Zhou, D.; Lin, R.; Wang, X.; Shi, B. Anticancer effects of miR-124 delivered by BM-MSC derived exosomes on cell proliferation, epithelial mesenchymal transition, and chemotherapy sensitivity of pancreatic cancer cells. Aging 2020, 12, 19660–19676.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medicine, Research & Experimental
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Ahmed Faris Aldoghachi
, Zhi Xiong Chong , Swee Keong Yeap ,
Soon Keng Cheong
, Wan Yong Ho , Alan Han Kiat Ong
View Times: 577
Revisions: 2 times (View History)
Update Date: 18 Jan 2023
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback